Image For Activity Cover
Fundamentals of SGLT2i’s and GLP-1RA’s for CV Risk
Description
Listen to Expert Faculty discuss the fundamental science and the mechanism to evidence around new antihyperglycemic drugs, and why exactly this is such an important topic. This conversation focuses on the key principles if adding GLP-1 RAs and SGLT2 inhibitors, and how using these drugs has been shown to have an important effect on reducing cardiovascular outcomes. 

Faculty:

Christopher Granger, MD, FACC
Professor of Medicine, Director, Cardiac Intensive Care Unit, Duke University Medical Center

Adam Nelson, MBBS
Duke Clinical Research Institute

Neha Pagidipati, MD
Assistant Professor of Medicine, Duke University Medical Center

Robert Eckel, MD
Professor of Medicine, Emeritus, University of Colorado Anschutz Medical Campus

Educational grant support provided by: Boehringer Ingelheim Lilly

Summary
Availability: On-Demand
Available May 19, 2020 to May 20, 2021
Cost: FREE
Credit Offered: No Credit Offered
Powered By